Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/16—Otologicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/38—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/38—Nitrogen atoms
  • C07D215/40—Nitrogen atoms attached in position 8
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
  • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
  • C07D217/24—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the invention relates to quinoline and isoquinoline derivatives, a process for their preparation and their use as anti-inflammatory agents.
• Ar residue comprises phthalides, thiophthalides, benzoxazinones or phthalazinones.
• the present invention therefore relates to compounds of the general formula
• A is an aryl, a benzyl or a phenethyl group, where the aryl, benzyl or phenethyl group may optionally be substituted by one or more radicals from the group Ci-Cs-alkyl, CrC 5 alkoxy, -CC 5 Alkylthio, C 1 -C 5 perfluoroalkyl, halogen, hydroxy, cyano, nitro,
• n 1 or 2 and the terminal oxygen atoms and / or carbon atoms are linked to directly adjacent ring carbon atoms, or NR 4 R 5 , where R 4 and R 5 independently of one another may be hydrogen, C 1 -C 5 -alkyl or (CO) -CrC 5 -alkyl,
• R 1 and R 2 independently of one another represent a hydrogen atom, a methyl or ethyl group or, together with the carbon atom of the chain, a C 3 -C 6 -cycloalkyl ring,
• R 3 is a C 1 -C 3 -alkyl group or an optionally partially or completely fluorinated C 1 -C 3 -alkyl group,
• B is an optionally substituted by a methyl or ethyl group methylene group or a carbonyl group and Q is attached via an arbitrary position quinolinyl or
• Isoquinolinyl group which may optionally be substituted by one or more radicals from the group of C 1 -C 4 -alkyl which may be optionally substituted by 1 -3 hydroxyl groups and / or 1 -3 COOR 6 groups, C 5 -alkoxy, C 1 -C 5 Alkylthio, C 1 -C 5 -perfluoroalkyl, halogen,
• R 4 and R 5 can be independently hydrogen, Ci-Cs-alkyl or (CO) -C-C 5 alkyl, COOR 6 , wherein R 6 is hydrogen or a C 1 -C 5 -alkyl group,
• R 7 and R 8 independently of one another denote hydrogen or a C 1 -C 5 -alkyl group, or denote a (C 1 -C 5 -alkylene) -O- (CO) - (C 1 -C 5 ) -alkyl group . as well as their racemates or separately present stereoisomers, and optionally their physiologically acceptable salts.
• the aryl group is preferred.
• the aryl group includes phenyl and naphthyl. Phenyl is preferred.
• substituted aryl, benzyl or phenethyl groups carry on the ring 1 to 3 substituents, preferably 2 substituents in addition to the linkage with the chain.
• substitution patterns on the ring A are a special subject of the invention: ' 2,5-Disubstituted phenyl derivatives and 2,4-disubstituted phenyl derivatives, wherein the 1-position is occupied by the link to the chain.
• Carbon atoms are linked to directly adjacent ring carbon atoms.
• the CC 5 alkyl groups in A, R 3 , R 4 , R 5 , R 6 , R 7 and R 8 can be straight-chain or branched and are methyl, ethyl, n-propyl, iso-propyl, n Butyl, iso-butyl, tert-butyl or n-pentyl, 2,2-dimethylpropyl, 2-methylbutyl or 3-methylbutyl group.
• a methyl or ethyl group is preferred. They may optionally be substituted by 1-3 hydroxy and / or 1-3 COOR 6 groups. Preference is given to hydroxy groups.
• Under a (-CC 5 -alkylene) -0- (CO) - (-CC 5 ) alkyl group is for example a -CH 2 -O-CO-CH 3 group to understand.
• a partially or fully fluorinated dC 3 alkyl group the following are partially or fully fluorinated groups: fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, 1, 1-difluoroethyl, 1, 2-difluoroethyl, 1, 1, 1 trifluoroethyl, tetrafluoroethyl , Pentafluoroethyl. Of these, preferred are the trifluoromethyl or the pentafluoroethyl group.
• the alkyl radicals R 1 and R 2 together with the carbon atom of the chain can form a 3 to 6-membered ring.
• the cyclopropyl ring is preferred.
• the C 1 -C 5 -alkoxy groups in A and Q may be straight-chain or branched and may be a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy or n Pentoxy, 2,2-dimethylpropoxy, 2-methylbutoxy or 3-methylbutoxy group.
• a methoxy or ethoxy group is preferred.
• the C 1 -C 5 -alkylthio groups in A and Q may be straight-chain or branched and may be a methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio or n-pentylthio , 2,2-dimethylpropylthio, 2-methylbutylthio or 3-methylbutylthio group.
• a methylthio or ethylthio group is preferred.
• halogen atom or halogen means a fluorine, chlorine, bromine or iodine atom. Preference is given to a fluorine, chlorine or bromine atom.
• the NR 4 R 5 group can be, for example, NH 2 , N (H) CH 3 , N (CH 3 ) 2 , N (H) (CO) CH 3 , N (CH 3 ) (CO) CH 3 , N [( CO) CH 3] 2, N (H) C0 2 CH 3, N (CH 3) C0 2 CH 3, N (CO 2 CH 3) 2 radical.
• alkyl radicals R 4 and R 5 -CC 3 alkyl are preferred.
• acyl radicals R 4 and R 5 (CO) -CC 3 -alkyl are preferred.
• NR 7 R 8 group for example, NH 2 , N (H) CH 3 , N (CH 3 ) 2 , N (C 2 H 5 ) 2 , NH (C 2 H 5 ), N (C 3 H 7 ) 2 , N (C 4 H 9 ) 2 , N (C 5 Hn) 2 in question.
• radical B the unsubstituted methylene group and the carbonyl group are preferred. Particularly preferred is the methylene group.
• An object of the invention are compounds of the formula I, wherein Q is an optionally substituted quinolinyl group linked via an arbitrary position.
• the radical Q may be linked via any ring carbon atom to the (NH) group of the chain.
• the 4-, 5-, and 8-positions are for the quinoline ring and the 1-position for the isoquinoline ring.
• Another object of the invention are the compounds of general formula I wherein
• A represents an aryl, a benzyl or a phenethyl group, it being possible for the aryl, benzyl or phenethyl group to be optionally substituted by one or more radicals from the group C 1 -C 5 -alkyl, C 1 -C -alkoxy, CC 5 Alkylthio, C 1 -C 5 -
• Isoquinolinyl group which may optionally be substituted by one or more radicals from the group C- ⁇ -C 5 -alkyl,
• R 4 and R 5 independently of one another may be hydrogen, C 1 -C 5 -alkyl or (CO) -C-C 5 -alkyl
• Another object of the invention are compounds of general formula I wherein Q is a linked via any position quinolinyl or
• Isochinolinyl which may optionally be substituted by one or more radicals from the group
• Ci-C ⁇ -alkyl group or a (CrC 5 alkyl) -0- (CO) - alkyl group (C 1 -C 5).
• An object of the invention are compounds of general formula I wherein Q represents a monosubstituted quinolinyl group.
• An object of the invention are compounds in which B is a methylene group and Q is an optionally substituted quinolinyl group.
• Another object of the invention are compounds in which A is an optionally substituted phenyl group, Q is an optionally substituted quinolinyl group and B is a methylene group.
• the compounds of the general formula I according to the invention can be present as different stereoisomers due to the presence of asymmetric centers. Both the racemates and the separately present stereoisomers are the subject of the present invention.
• a particular object of the present invention are the separately present stereoisomers, i. (+) - enantiomers and (-) - enantiomers.
• the compounds according to the invention are characterized by the presence of a keto-enol tautomerism.
• both forms form the subject of the invention, even if, e.g. in the experimental part, only one of the two tautomeric forms has been listed.
• the present invention further relates to processes for the preparation of the compounds of the formula I, as well as their use for the preparation of medicaments.
• the use for the preparation of medicaments for the treatment of diseases whose cause is inflammatory processes is likewise an object of the invention.
• R 3 has the abovementioned meaning and R 9 denotes a C 1 -C 5 -alkyl group, in the presence of a catalyst, for example fluoride salts or bases, such as alkali metal carbonates (J. Am. Chem. Soc., 1989, 111, 393), to give the title compound (I).
• a catalyst for example fluoride salts or bases, such as alkali metal carbonates (J. Am. Chem. Soc., 1989, 111, 393), to give the title compound (I).
• ⁇ -keto acids (II) can also be converted into compounds (V),
• R 1 and R 2 are as defined above and R 10 is C 1 -C 4 -alkyl, are esterified by conventional methods, for example with thionyl chloride in methanol or ethanol or with methyl iodide and alkali metal carbonate, and in analogy to the reaction sequence A1) of (III) in (I) can be converted into compound (VI).
• This is used for coupling with an aminoquinoline or aminoisoquinoline or a (partially) hydrogenated quinoline or isoquinoline derivative (Q-NH 2 ) using a common activating reagent, for example thionyl chloride, optionally in the presence of a catalyst such as dimethylaminopyhdin, to give the title compound ( I) implemented.
• a common activating reagent for example thionyl chloride, optionally in the presence of a catalyst such as dimethylaminopyhdin, to give the title compound ( I) implemented.
• B) for B an optionally substituted by methyl or ethyl methylene group
• A, B and R 1 , R 2 and R have the abovementioned meaning and LG is any leaving group such as halide or sulfonate, is reacted with a compound of general formula (IX) or (X)
• R 12 is a hydrogen atom, a C 1 -C 5 -acyl group or alkoxy or aryloxycarbonyl group and Q has the abovementioned meaning, where the R 12 radical is split off or an intermediate oxazolidinone (cf., for example, SJ Brickner, DK Hutchinson, MR Barbachyn, PR Manninen, DA Ulanowicz, SA Garmon, KC Grega, SK Hendges, DS Toops, CW Ford, GE Zurenko J. Med. Chem. 1996, 39, 673) is cleaved with, for example, aqueous alkali hydroxides to give the title compound (I).
• an intermediate oxazolidinone cf., for example, SJ Brickner, DK Hutchinson, MR Barbachyn, PR Manninen, DA Ulanowicz, SA Garmon, KC Grega, SK Hendges, DS Toops, CW Ford, GE Zurenko
• Another way is to react compounds of formula (VII) or (VIII) with nitrogen nucleophiles, for example azide salts or ammonia, in the first case a reduction in the manner known to those skilled in the art, e.g. with complex hydride reagents, such as lithium aluminum hydride, or by a transition metal-catalyzed hydrogenolysis followed to obtain compounds of formula (XI).
• nitrogen nucleophiles for example azide salts or ammonia
• Compound (XI) may be subject to base catalysis, e.g. in the presence of tertiary amine bases or alkali carbonates or hydroxides, or under
• Transition metal catalysis e.g. Palladium catalysis (JP Wolfe, S. Wagaw, J.-F. Marcoux, SL Buchwald Acc. Chem. Res. 1998, 31, 805; JF Hartwig Acc. Chem. Res. 1998, 31, 852), with a halogenated quinoline or Isoquinoline are converted to the title compound (I).
• Palladium catalysis JP Wolfe, S. Wagaw, J.-F. Marcoux, SL Buchwald Acc. Chem. Res. 1998, 31, 805; JF Hartwig Acc. Chem. Res. 1998, 31, 852
• the title compound (I) can also be synthesized by reductive amination of a compound of the formula (XII) with Q-NH 2 , with, for example, sodium cyanoborohydride or sodium triacetoxyborohydride being suitable as the reducing agent.
• R 1 is methyl or ethyl according to the substituents defined for the methylene group in B.
• this may be, for example, in the form of the hydrochloride, sulfate, nitrate, phosphate, pivalate, maleate, fumarate, tartrate, benzoate, mesylate, citrate or succinate.
• the compounds according to the invention are present as racemic mixtures, they can be separated into the pure optically active forms by methods of racemate resolution which are familiar to the person skilled in the art.
• the racemic mixtures can be separated by chromatography on a self-optically active support material (CHIRALPAK AD®) into the pure isomers.
• CHIRALPAK AD® self-optically active support material
• the optically active acid for example, mandelic acid, camphorsulfonic acid or tartaric acid can be used.
• glucocorticoid receptor GR
• other steroid hormone receptors mineral corticoid receptor (MR), progesterone receptor (PR) and androgen receptor (AR)
• Cytosol preparations of Sf9 cells infected with recombinant baculoviruses encoding the GR are used for the binding assays.
• the substances show a high to very high affinity for GR.
• the quinolines and isoquinolines of formula (I) described herein show high selectivity for the glucocorticoid receptor.
• GR-mediated inhibition of transcription of cytokines, adhesion molecules, enzymes, and other pro-inflammatory factors is considered. This inhibition is mediated by an interaction of the GR with other transcription factors, e.g. AP-1 and NF-kappa B (for review see Cato, ACB and Wade E, BioEssays 18, 371-378 1996).
• the compounds of the general formula I according to the invention inhibit lipopolysaccharide (LPS) -derived secretion of the cytokine IL-8 in the human monocyte cell THP-1.
• LPS lipopolysaccharide
• the concentration of cytokines was determined in the supernatant by means of commercially available ELISA kits.
• the anti - inflammatory activity of the compounds of the general formula I were induced in the animal experiment by testing in the croton oil - induced
• Peroxidase activity measured as a measure of granulocytic immigration and elastase activity as a measure of immigration of neutrophils.
• the compounds of the general formula I inhibit the three abovementioned inflammatory parameters in this test both after topical and after systemic administration.
• glucocorticoid therapy One of the most common adverse effects of glucocorticoid therapy is the so-called "steroid diabetes" [cf. Hatz, HJ, Glucocorticoids: Immunological Foundations, Pharmacology and Therapy Guidelines, Horschafliche Verlagsgesellschaft mbH, Stuttgart, 1998].
• the reason for this is the stimulation of gluconeogenesis in the liver by induction of the responsible enzymes and by free amino acids, which arise from the degradation of proteins (catabolic effect of glucocorticoids).
• a key enzyme of catabolic metabolism in the liver is tyrosine aminotransferase (TAT). The activity of this enzyme can be determined photometrically from liver homogenates and represents a good measure of the undesired metabolic effects of the glucocorticoids.
• the animals are sacrificed 8 hours after administration of the test substances, the liver is removed and the TAT activity in the Homogenate measured.
• the compounds of general formula I do not or only to a limited extent induce tyrosine aminotransferase in doses in which they are anti-inflammatory in this test.
• the compounds of the general formula I according to the invention can be used as medicaments for the treatment or prophylaxis of the following disease states in mammals and humans:
• the term "DISEASE” stands for the following indications:
• Pulmonary diseases associated with inflammatory, allergic and / or proliferative processes - Chronic obstructive pulmonary diseases of any genesis, especially
• rheumatic diseases especially rheumatoid arthritis, acute rheumatic fever, polymyalgia rheumatica
• Traumatic arthritis - collagenosis of any genesis e.g. systemic lupus erythematosus
• Erythematous diseases triggered by different noxae e.g. Blasting, chemicals, burns etc.
• kidney disease associated with inflammatory, allergic and / or proliferative processes (vi) kidney disease associated with inflammatory, allergic and / or proliferative processes:
• liver disease associated with inflammatory, allergic and / or proliferative processes (vii) liver disease associated with inflammatory, allergic and / or proliferative processes:
• acute hepatitis of different origins e.g. viral, toxic, drug-induced - chronic aggressive and / or chronic intermittent hepatitis
• Severe states of shock such as anaphylactic shock, systemic inflammatory response syndrome (SIRS) (xviii) Substitution therapy for: congenital primary adrenal insufficiency, e.g. Congenital adrenogenital syndrome
• Acquired primary adrenal insufficiency e.g. Addison's disease, autoimmune adrenalitis, postinfectious, tumors, metastases, etc.
• congenital secondary adrenal insufficiency e.g. congenital
• the compounds of the general formula I according to the invention can be used for the therapy and prophylaxis of other disease states not mentioned above, for which synthetic glucocorticoids are used today (see Hatz, HJ, Glucocorticoids: Immunological Principles, Pharmacology and Therapy Guidelines, Horschafliche Verlagsgesellschaft mbH, Stuttgart , 1998).
• the suitable dose is different and depends, for example, on the potency of the compound of general formula I, the host, the mode of administration and the nature and severity of the conditions to be treated, as well as the use as a prophylactic or therapeutic agent.
• the invention further provides
• a recommended daily dose is in the range of 1 ⁇ g to 100,000 ⁇ g per kg of body weight.
• a dose of 10 to 30,000 ⁇ g per kg body weight more preferably a dose of 10 to 10,000 ⁇ g per kg body weight.
• this dose is conveniently administered several times a day.
• an acute shock e.g., anaphylactic shock
• single doses well above the above doses may be given.
• the formulation of the pharmaceutical preparations based on the novel compounds is carried out in a manner known per se by reacting the active substance with the carriers customarily used in galenicals, fillers, disintegrators, binders, humectants, lubricants, Absorbents, diluents, flavoring agents, colorants, etc., processed and converted into the desired application form.
• the carriers customarily used in galenicals, fillers, disintegrators, binders, humectants, lubricants, Absorbents, diluents, flavoring agents, colorants, etc.
• crystal suspensions For intraarticular injection, appropriately prepared crystal suspensions may be used.
• aqueous and oily injection solutions or suspensions and corresponding depot preparations can be used.
• the new compounds may be used in the form of suppositories, capsules, solutions (e.g., in the form of enemas) and ointments for both systemic and local therapy.
• these can be used in the form of aerosols and inhalants.
• the new compounds may be used as drops, ointments and tinctures in appropriate pharmaceutical preparations.
• compositions in gels, ointments, greases, creams, pastes, powders, milk and tinctures are possible.
• the dosage of Compounds of general formula I should be in these preparations 0.01% - 20% in order to achieve a sufficient pharmacological effect.
• the invention also encompasses the compounds of general formula I according to the invention as therapeutic active ingredient. Furthermore belongs to the
• the invention also includes a pharmaceutical composition containing one of the pharmaceutically active compounds of the invention or their mixture or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable salt or excipients and excipients.
• N- (quinolin-4-yl) -4- (5-fluoro-2-methoxyphenyl) -4-methyl-2-oxo-pentanoic acid amide which is dissolved in 22 ml of DMF and cooled to 0 ° C.
• the solution is mixed with 1.80 ml (trifluoromethyl) trimethylsilane and 2.43 g of cesium carbonate and stirred for 16 h at room temperature. Water is added, extracted with ethyl acetate, the organic phase is washed with water and dried over sodium sulfate.
• the concentrated intermediate is taken up in 10 ml of THF and 5.5 ml of a 1 M solution of tetrabutylammonium fluoride are added.
• Ethyl 4- (5-bromo-2-methoxyphenyl) -4-methyl-2-oxopentanoate 9.8 g of 1- (5-bromo-2-methoxyphenyl) -1-methylethanol and 15.24 g of ethyl 2- (trimethylsilyloxy) acrylate in 150 ml of dichloromethane are added at -70 ° C with 5.6 ml of tin tetrachloride. After 20 minutes at -70 ° C, the solution is poured onto a semi-saturated potassium carbonate solution and treated with dichloromethane.
• N- (Quinolin-5-yl) -4-methyl-2-oxo-4-phenylpentanamide From 515 mg of 4-methyl-2-oxo-4-phenyl-pentanoic acid (WO98 / 54159) are prepared according to the procedure for 4- ( 1,3-Benzodioxol-4-yl) -N- (quinolin-5-yl) -4-methyl-2-oxopentanamide (Example 12) after chromatography on silica gel 370 mg of N- (quinolin-5-yl) -) 4-methyl-2-oxo-4-phenylpentanamide obtained. Fp.:98-99°C
• N- (Quinolin-5-yl) -) - 2-hydroxy-4-methyl-4-phenyl-2- (trifluoromethyl) pentanamide From 200 mg of N- (quinolin-5-yl) -4-methyl-2-oxo 4-phenylpentanamide are prepared according to the instructions for 4- (1, 3-benzodioxol-4-yl) -N- (quinolin-5-yl) -2-hydroxy-4-methyl-2- (trifluoromethyl) pentanamide (Example 12 After chromatography on silica gel 85 mg of N- (quinolin-5-yl) -2-hydroxy-4-methyl-4-phenyl-2- (trifluoromethyl) pentanamide. Mp .: 181-182 ° C
• Hexane-ethyl acetate purified 660 mg of a yellow solid.
• Pd-C are added in 25 mL of ethyl acetate for 2 h in a hydrogen atmosphere
• aqueous phase is extracted with dichloromethane, the combined organic phases are dried over sodium sulphate and the solvent is removed in vacuo. After purification on silica gel with hexane-ethyl acetate (0-100%), 400 mg (66% of theory) of the product are obtained.
• Acetone and methanol provide 257 mg (67% of theory) of the product.
• the reaction solution is concentrated to one third of the original volume and added to ice-water. It is extracted with ethyl acetate, the combined organic phases are washed with saturated sodium bicarbonate solution, then with saturated sodium chloride solution, dried on sodium sulfate and the solvent is removed in vacuo.
• the crude product is dissolved in 80 mL methanol-acetone (50%) and treated with palladium on carbon and potassium carbonate. It is stirred for 20 hours under a hydrogen atmosphere at room temperature. After filtering off with suction through Celite and washing with acetone, the solvent is removed in vacuo and the residue is purified on silica gel with hexane-ethyl acetate (0-60%). 850 mg (27% of theory) of the product are obtained.
• Methyl 5- [4- (4-chloro-2-methoxyphenyl) -2-hydroxy-4-methyl-2- (trifluoromethyl) pentylideneamino] quinoline-2-carboxylate Analogously to Example 1, 250 mg (1.24 mmol) of 5-aminoquinoline 2-Carboxylic acid methyl ester with 484 mg (1.49 mmol) of 4- (4-chloro-2-methoxyphenyl) -2-hydroxy-4-methyl-2- (trifluoromethyl) pentanal and 1.40 mL of conc. Acetic acid in 20 mL of toluene reacted.
• Tetrahydrofuran adds 0.3 mL (1.4 mmol) of titanium tetraethylate and leaves the
• Analpg to Example 38 are 80 mg (0.15 mmole) of 4- (5-flupr-2-methexyphenyl) -
• Trimethylsilyloxy-acrylic acid ethyl ester (WO 00/32584) in 36 ml of dichloromethane at -70 ° C with 1.10 ml of tin (VI) chloride are added. It will take 20 min. stirred at -70 ° C and then sat. Sodium carbonate solution given. It is extracted with dichloromethane, washed with water, dried and concentrated in vacuo. This gives 3.15 g of 4- (7-bromo-1, 3-benzodioxol-4-yl) -4-methyl-2-oxo valeric acid ethyl ester as crude product.
• a solution of 160 mg of 4- (7-bromo-1,3-benzodioxol-4-yl) -2-hydroxy-4-methyl-2- (trifluoromethyl) -pentan-1-ol and 111 mg of 4-toluenesulfonyl chloride in 1.5 ml Pyridine are stirred at 0 ° C for 70 h.
• MS mass spectrometry
• mp melting point (fixed point)

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Dermatology (AREA)
• Oncology (AREA)
• Pulmonology (AREA)
• Communicable Diseases (AREA)
• Virology (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Epidemiology (AREA)
• Neurology (AREA)
• Transplantation (AREA)
• Endocrinology (AREA)
• Ophthalmology & Optometry (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Neurosurgery (AREA)
• Cardiology (AREA)
• Pain & Pain Management (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Biotechnology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (22)

Applications Claiming Priority (2)

Publications (1)

Family

ID=28458623

Family Applications (1)

Country Status (32)

Cited By (88)

Families Citing this family (2)

Citations (1)

Family Cites Families (4)

• 2002
  • 2002-04-02 DE DE10215316A patent/DE10215316C1/de not_active Expired - Lifetime
• 2003
  • 2003-03-29 BR BR0308967-3A patent/BR0308967A/pt not_active IP Right Cessation
  • 2003-03-29 WO PCT/EP2003/003298 patent/WO2003082827A1/de not_active Ceased
  • 2003-03-29 MX MXPA04009684A patent/MXPA04009684A/es active IP Right Grant
  • 2003-03-29 ME MEP-142/08A patent/MEP14208A/xx unknown
  • 2003-03-29 PL PL372884A patent/PL212322B1/pl unknown
  • 2003-03-29 HR HRP20041005AA patent/HRP20041005B1/hr not_active IP Right Cessation
  • 2003-03-29 ME MEP-2008-142A patent/ME00159B/me unknown
  • 2003-03-29 AT AT03745195T patent/ATE355277T1/de active
  • 2003-03-29 CA CA2481012A patent/CA2481012C/en not_active Expired - Fee Related
  • 2003-03-29 PT PT03745195T patent/PT1492771E/pt unknown
  • 2003-03-29 ES ES03745195T patent/ES2282649T3/es not_active Expired - Lifetime
  • 2003-03-29 SI SI200330748T patent/SI1492771T1/sl unknown
  • 2003-03-29 UA UA20041108938A patent/UA78304C2/uk unknown
  • 2003-03-29 AU AU2003215678A patent/AU2003215678B2/en not_active Ceased
  • 2003-03-29 EA EA200401294A patent/EA008540B1/ru not_active IP Right Cessation
  • 2003-03-29 NZ NZ535872A patent/NZ535872A/en not_active IP Right Cessation
  • 2003-03-29 EP EP03745195A patent/EP1492771B1/de not_active Expired - Lifetime
  • 2003-03-29 DE DE50306659T patent/DE50306659D1/de not_active Expired - Lifetime
  • 2003-03-29 JP JP2003580295A patent/JP4593929B2/ja not_active Expired - Fee Related
  • 2003-03-29 DK DK03745195T patent/DK1492771T3/da active
  • 2003-03-29 RS YUP-868/04A patent/RS50931B/sr unknown
  • 2003-03-29 KR KR1020047015697A patent/KR100967277B1/ko not_active Expired - Fee Related
  • 2003-03-29 CN CN038126842A patent/CN1659144B/zh not_active Expired - Fee Related
  • 2003-04-02 AR ARP030101145A patent/AR039222A1/es active IP Right Grant
  • 2003-04-02 PE PE2003000334A patent/PE20040081A1/es not_active Application Discontinuation
  • 2003-04-02 UY UY27748A patent/UY27748A1/es not_active Application Discontinuation
  • 2003-04-02 TW TW092107522A patent/TWI272267B/zh not_active IP Right Cessation
• 2004
  • 2004-09-27 IL IL164292A patent/IL164292A/en not_active IP Right Cessation
  • 2004-10-29 EC EC2004005399A patent/ECSP045399A/es unknown
  • 2004-11-01 NO NO20044731A patent/NO329668B1/no not_active IP Right Cessation
  • 2004-11-01 ZA ZA200408827A patent/ZA200408827B/xx unknown
• 2006
  • 2006-06-13 US US11/451,508 patent/US7329753B2/en not_active Expired - Fee Related
• 2007
  • 2007-05-17 CY CY20071100665T patent/CY1106598T1/el unknown

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events